{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:41:11Z","timestamp":1767850871170,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0010569","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000}}],"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["J\/423\/2252"],"award-info":[{"award-number":["J\/423\/2252"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Treatment of Cutaneous leishmaniasis (CL) is based on using antimoniate derivatives; patients\u2019 compliance for systemic injections is low due to the pain and systemic complications. In this randomized open trial, the efficacy of intra-lesional (IL) injections of meglumine antimoniate (MA) once a week <jats:italic>vs<\/jats:italic>. twice a week in the treatment of Anthrpoponothic CL caused by <jats:italic>L<\/jats:italic>. <jats:italic>tropica<\/jats:italic> was studied. Eligible volunteer patients were selected according to inclusion\/exclusion criteria. The included patients were randomly allocated to receive IL-MA injections once a week or twice a week. The primary outcome was set as complete healing of the lesion(s), and defined as complete re-epithelialization and absence of induration in the lesions. A total of 180 parasitologicaly proven CL patients caused by <jats:italic>L<\/jats:italic>. <jats:italic>tropica<\/jats:italic> were recruited, 90 patients were treated with weekly IL-MA and 90 patients received IL-MA twice a week. The complete cure was 87.9% vs. 89.2% in the group received weekly and twice a week IL-MA injections, respectively (P = 0.808). Patients\u2019 compliance was acceptable and side effects were limited to a few local allergic reactions to MA. Median time to healing was significantly shorter in patients who received IL-MA twice a week (median \u00b1 SE) 37\u00b13.8, (CI: 29.6\u201344.4) days compared to whom received IL-MA once a week 60\u00b12.3, (CI: 55.6\u201364.5) days (P&lt; 0.001), however the number of injections was higher in group who received IL-MA twice a week (12 vs. 9 injections). In conclusion, the rate of cure in the group of CL patients with IL-MA twice a week was not significantly different from the group who received IL-MA once a week shorten, but the duration of healing was shorter in the group who received IL-MA twice a week while the group received more injections so is recommended to use IL-MA once a week due to the fact the compliance is acceptable with limited side effects.<\/jats:p>\n<jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold> IRCT20081130001475N13; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/\" xlink:type=\"simple\">https:\/\/en.irct.ir\/<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pntd.0010569","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T18:15:57Z","timestamp":1657304157000},"page":"e0010569","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-4583","authenticated-orcid":true,"given":"Amir","family":"Javadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ghoorchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdieh","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ebrahim","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Fekri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Reza","family":"Aflatoonian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Firooz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"pntd.0010569.ref001","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis Worldwide and Global Estimates of Its Incidence.","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLOS ONE."},{"key":"pntd.0010569.ref002","unstructured":"Leishmaniasis. In: World Health Organization [Internet]. [cited 4 Oct 2020]. Available: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis."},{"key":"pntd.0010569.ref003","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0738-081X(96)00058-2","article-title":"Cutaneous leishmaniasis: Clinical aspect.","volume":"14","author":"Y. Dowlati","year":"1996","journal-title":"Clin Dermatol"},{"key":"pntd.0010569.ref004","first-page":"299","article-title":"A comprehensive review of cutaneous leishmaniasis in kerman province, southeastern iran-narrative review article.","author":"I Sharifi","year":"2015","journal-title":"Iran J Public Health."},{"key":"pntd.0010569.ref005","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2014challenges and opportunities","volume":"17","author":"SL Croft","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"pntd.0010569.ref006","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in Combination With Meglumine Antimoniate for Cutaneous Leishmaniasis: A Randomized Assessor-Blind Controlled Trial","volume":"142","author":"A Firooz","year":"2006","journal-title":"Arch Dermatol"},{"key":"pntd.0010569.ref007","unstructured":"Shirzadi MR. Statistics of cutaneous leishmanaisis in Iran: National Leishmaniasis Committee. 1st Meeting of National Leishmaniasis Network, IRAN: Center of Disease Control, Ministry of Health and Medical Education.; 2010 Aug."},{"key":"pntd.0010569.ref008","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites.","volume":"3","author":"R Hadighi","year":"2006","journal-title":"PLOS Med."},{"key":"pntd.0010569.ref009","doi-asserted-by":"crossref","first-page":"335.e1","DOI":"10.1016\/j.jaad.2007.01.016","article-title":"Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials","volume":"57","author":"A Khatami","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"pntd.0010569.ref010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-9292-6-3","article-title":"Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13\u201315 June, 2006.","volume":"6","author":"F Modabber","year":"2007","journal-title":"Kinetoplastid Biol Dis."},{"key":"pntd.0010569.ref011","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14712598.2014.945415","article-title":"Therapeutic vaccines for leishmaniasis.","volume":"14","author":"A. Khamesipour","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"pntd.0010569.ref012","first-page":"513","article-title":"Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis","volume":"17","author":"MN Kashani","year":"2007","journal-title":"Eur J Dermatol EJD"},{"key":"pntd.0010569.ref013","article-title":"Interventions for Old World cutaneous leishmaniasis.","author":"U Gonz\u00e1lez","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"pntd.0010569.ref014","doi-asserted-by":"crossref","first-page":"e0184777","DOI":"10.1371\/journal.pone.0184777","article-title":"Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.","volume":"12","author":"NC Brito","year":"2017","journal-title":"PLOS ONE."},{"key":"pntd.0010569.ref015","first-page":"73","article-title":"Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial.","volume":"4","author":"A Firooz","year":"2005","journal-title":"J Drugs Dermatol JDD"},{"key":"pntd.0010569.ref016","first-page":"85","article-title":"Comparison of topical paromomycin sulfate (twice\/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.","volume":"15","author":"B Shazad","year":"2005","journal-title":"Eur J Dermatol EJD"},{"key":"pntd.0010569.ref017","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2010.09865.x","article-title":"Efficacy of short-duration (twice weekly) intralesional sodium stibogluconate in treatment of cutaneous leishmaniasis in India.","volume":"163","author":"RA Bumb","year":"2010","journal-title":"Br J Dermatol"},{"key":"pntd.0010569.ref018","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-4362.1999.00769.x","article-title":"Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis","volume":"38","author":"G Mujtaba","year":"1999","journal-title":"Int J Dermatol"},{"key":"pntd.0010569.ref019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1542\/peds.95.6.882","article-title":"Intralesional Treatment of Cutaneous Leishmaniasis with Sodium Stibogluconate Antimony","volume":"95","author":"RM Faris","year":"1995","journal-title":"Pediatrics"},{"key":"pntd.0010569.ref020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1468-3083.2009.03157.x","article-title":"Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate.","volume":"23","author":"M Solomon","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"pntd.0010569.ref021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/09546639809160700","article-title":"Weekly versus every 3 days intralesional meglumine antimoniate therapy for cutaneous leishmaniasis","volume":"9","author":"M Radmanesh","year":"1998","journal-title":"J Dermatol Treat"},{"key":"pntd.0010569.ref022","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-4362.1996.tb03669.x","article-title":"Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate","volume":"35","author":"TM Tallab","year":"1996","journal-title":"Int J Dermatol"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0010569","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T17:52:56Z","timestamp":1658944376000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010569"}},"subtitle":[],"editor":[{"given":"Hira L.","family":"Nakhasi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010569","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0010569","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}